Prilosec OTC
Executive Summary
AstraZeneca/Procter & Gamble's Prilosec OTC clears FDA June 20 in 28- and 42-count package sizes to limit duration of use to 14 consecutive days and up to three courses per year. P&G plans to launch OTC omeprazole in the fall; approval follows completion of a label comprehension study as requested by FDA in an Aug. 8, 2002 "approvable" letter (1"The Pink Sheet" Aug. 26, 2002, p. 11)...
You may also be interested in...
Prilosec OTC Switch Set For Early 2003 Following FDA “Approvable” Letter
AstraZeneca's OTC switch for Prilosec (omeprazole) will wait until 2003 after receipt of an "approvable" letter from FDA
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.